Vanillylmandelic acid

- Rapid and sensitive detection of vanillylmandelic acid based on a luminescent fourteen-metal Tb(III) planar nanocluster
- Surgical Candidacy in Skull Base Paragangliomas: An Institutional Experience
- Surgical strategy for an adult patient with a catecholamine-producing ganglioneuroblastoma and a cerebral aneurysm: a case report
- Giant melanotic neuroectodermal tumor of infancy (melanotic progonoma) of the head and neck: report of a malignant case
- Neuroblastoma
- A Novel Swine Model of Spontaneous Hypertension With Sympathetic Hyperactivity Responds Well to Renal Denervation
- Monoamine metabolites in ventricular CSF of children with posterior fossa tumors: correlation with tumor histology and cognitive functioning
- Cardiovascular effects of vanillylmandelic acid in rats

Vanillylmandelic acid (VMA) is a metabolite of **catecholamines**, specifically **epinephrine** (adrenaline) and **norepinephrine** (noradrenaline). It is formed when these neurotransmitters are broken down in the body. VMA is primarily excreted in the urine and is used in clinical settings as a biomarker for certain medical conditions.

Key Points about VMA:

1. **Chemical Structure**:

    1. VMA is a **phenolic** compound with the chemical name **4-hydroxy-3-methoxyphenylacetic acid**.
    2. It is produced through the metabolism of **catecholamines** (dopamine, norepinephrine, and epinephrine), specifically by the **methylation** of the precursor metabolites **normetanephrine** and **metanephrine**, followed by oxidative conversion.

2. **Metabolic Pathway**:

    1. The pathway begins when **epinephrine** and **norepinephrine** are metabolized by enzymes such as **catechol-O-methyltransferase (COMT)** and **monoamine oxidase (MAO)**.
    2. **Norepinephrine** is converted to **normetanephrine**, and **epinephrine** to **metanephrine**. Both are then further oxidized to form **vanillylmandelic acid**.

3. **Clinical Significance**:

    1. **VMA levels** are measured in urine as part of diagnostic tests for conditions associated with abnormal catecholamine production. Elevated levels of VMA can indicate:
        1. **Pheochromocytoma**: A tumor of the adrenal glands that causes excessive secretion of catecholamines.
        2. **Neuroblastoma**: A type of cancer that arises from nerve tissue, often in children, that can produce high amounts of catecholamines.
    2. VMA levels can also be elevated in other conditions involving excess catecholamine production,

such as **paragangliomas** and certain **ganglioneuromas**.

4. **Diagnostic Testing**:

1. The **VMA test** typically involves collecting **24-hour urine** to measure the concentration of VMA. A **high level of VMA** can indicate the presence of catecholamine-secreting tumors.
2. The test is often used as a screening tool for **pheochromocytoma** and **neuroblastoma**.
3. It's important to note that certain foods, medications (like **vanillin**, found in vanilla), or stress can influence VMA levels, so patients are often asked to avoid certain foods or medications before the test.

5. **Normal Range**:

1. The normal range of VMA excretion in urine varies depending on age and sex, but it is typically **1-6 mg per 24 hours** in adults. Values can vary slightly depending on the laboratory and methodology used.

6. **Applications**:

1. **VMA testing** is commonly used in pediatric oncology to screen for **neuroblastoma**, especially in patients presenting with symptoms such as abdominal masses, bone pain, or unexplained weight loss.
2. It is also used in **endocrinology** to monitor **pheochromocytomas**, where **surgical removal of the tumor** is a common treatment.

Summary: Vanillylmandelic acid is an important biomarker in clinical diagnostics, particularly for detecting **pheochromocytomas**, **neuroblastomas**, and other tumors that affect catecholamine production. Its measurement is often done through **urinary testing**, providing a relatively non-invasive method to monitor patients suspected of having these conditions.

The article **“Rapid and sensitive detection of vanillylmandelic acid based on a luminescent fourteen-metal Tb(III) planar nanocluster”** (Chem Commun, 2024 Nov 13. doi: 10.1039/d4cc03667k) by Yanheng Meng et al. presents an innovative approach for the detection of vanillylmandelic acid (VMA) using a **luminescent Tb(III) nanocluster** [1)].

This research highlights the construction of a **14-metal Tb(III) planar nanocluster** as a **luminescent probe** for detecting VMA with **high sensitivity** and **selectivity**.

Strengths:

1. **Innovative Approach**:

1. The use of a **14-metal Tb(III) nanocluster** as a luminescent sensor is highly novel. Tb(III), a rare earth element with strong luminescent properties, is a valuable choice for sensitive detection applications. The development of this planar nanocluster adds a new dimension to luminescence-based biosensing technologies.
2. The **CO32- anions as templates** for assembling the nanocluster represent an interesting strategy for controlling the nanostructure and enhancing its performance, which could be applied to other types of sensors in the future.

2. **Sensitivity and Speed**:

1. The **sensitivity** of this detection method is impressive, with a **limit of detection as low as 0.32 nM** in **CH3CN** (acetonitrile), a solvent commonly used in analytical chemistry. This low detection limit is crucial for detecting trace amounts of VMA, which can be important in clinical diagnostics where early detection of biomarkers is critical.
2. The **rapid response time of less than ten seconds** makes this method suitable for real-time analysis, which is a significant advantage over traditional detection techniques that may be slower and require more complex procedures.

3. **Selectivity**:

1. The paper emphasizes the **selectivity** of the nanocluster for VMA, an important aspect in ensuring that the sensor does not give false positives or interfere with other compounds in the sample. This is particularly relevant in clinical or environmental settings where various compounds may be present in the sample matrix.

4. **Potential Clinical and Research Applications**:

1. The ability to detect VMA with high sensitivity and selectivity holds potential for **clinical applications**, especially in the detection of neuroendocrine tumors like **pheochromocytoma** and **neuroblastoma**, where VMA is a critical biomarker. A sensor like this could enable **point-of-care diagnostics**, offering faster and potentially cheaper alternatives to conventional methods.
2. **Environmental monitoring** and **biochemical research** could also benefit from this detection method, providing a platform for the detection of other biomolecules with similar structural features.

Weaknesses:

1. **Solvent Dependence**:

1. The detection limit of **0.32 nM in CH3CN** suggests that the performance of the nanocluster is optimized in acetonitrile. However, the practical use of this method in biological or clinical samples would likely require the sensor to perform well in aqueous environments or complex matrices, which can introduce challenges such as matrix interference. Further validation in more complex sample types (e.g., urine, blood, or tissue extracts) is necessary to determine whether the sensor can maintain its high performance in real-world scenarios.

2. **Nanocluster Stability**:

1. While the study demonstrates rapid and sensitive detection, the **long-term stability** of the nanocluster in real-world conditions, such as exposure to different environmental factors, temperature, or varying pH, is not addressed in the abstract. The **physical and chemical stability** of the nanocluster under these conditions would be critical for its practical deployment in diagnostic applications.

3. **Mechanism of Interaction with VMA**:

1. While the article presents the sensitivity and speed of the sensor, the exact **mechanism of interaction between the nanocluster and VMA** is not fully explained in the abstract. Understanding how the Tb(III) nanocluster interacts with VMA at the molecular level—whether through electrostatic interactions, coordination bonding, or another mechanism—would provide

deeper insights into how the sensor works and help optimize its design for broader applications.

4. **Scalability and Cost**:

1. The scalability and cost-effectiveness of synthesizing the **14-metal Tb(III) planar nanocluster** are not discussed. **Synthetic complexity** and material costs can be limiting factors for widespread adoption of this technology in commercial applications, especially in low-resource settings.

Suggestions for Future Research:

- **Evaluation in Biological Samples**: Future studies should investigate the performance of the Tb(III) nanocluster-based sensor in **biological fluids** like blood, urine, or plasma. This would help assess its potential for clinical use, particularly in detecting low levels of VMA in the context of diseases like pheochromocytoma or neuroblastoma.

- **Mechanistic Studies**: A detailed understanding of the **interaction mechanism** between VMA and the nanocluster would improve sensor optimization and guide the design of future sensors targeting other metabolites or biomarkers.

- **Stability Testing**: Long-term testing of the nanocluster's **chemical and physical stability** under various conditions would be essential for ensuring its practicality in real-world applications.

- **Scaling Up for Commercial Use**: Research into **scalability** and **cost-effectiveness** of the nanocluster synthesis could make this technology more accessible for routine clinical or environmental testing.

Conclusion:

The study presents an exciting advancement in biosensing technology, with a **luminescent 14-metal Tb(III) nanocluster** that offers rapid, sensitive, and selective detection of vanillylmandelic acid. This approach holds significant promise for **clinical diagnostics**, particularly for diseases associated with altered catecholamine metabolism, as well as in **research** and **environmental monitoring**. However, further research into its **biological compatibility**, **interaction mechanisms**, and **long-term stability** will be important for translating this technology into widespread practical use.

Vanillylmandelic acid for neuroblastoma diagnosis

Vanillylmandelic acid for neuroblastoma diagnosis

1)
Meng Y, Wang S, Lv X, Huang X, Zhang W, Wu X, Schipper D, Yang X. Rapid and sensitive detection of vanillylmandelic acid based on a luminescent fourteen-metal Tb(III) planar nanocluster. Chem Commun (Camb). 2024 Nov 13. doi: 10.1039/d4cc03667k. Epub ahead of print. PMID: 39535599.